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Abstract
Aims/hypothesis The aim of this study was to investigate
the genetic aetiology of permanent diabetes mellitus with
onset in the first 12 months of age.
Methods We studied 46 probands with permanent, insulin-
requiring diabetes with onset within the first 6 months of
life (permanent neonatal diabetes mellitus [PNDM]/
monogenic diabetes of infancy [MDI]) (group 1) and eight
participants with diabetes diagnosed between 7 and
12 months of age (group 2). KCNJ11, INS and ABCC8
genes were sequentially sequenced in all patients. For those
who were negative in the initial screening, we examined
ERN1, CHGA, CHGB and NKX6-1 genes and, in selected
probands, CACNA1C, GCK, FOXP3, NEUROG3 and
CDK4. The incidence rate for PNDM/MDI was calculated
using a database of Italian patients collected from 1995 to
2009.
Results In group 1 we found mutations in KCNJ11, INS and
ABCC8 genes in 23 (50%), 9 (19.5%) and 4 (8.6%) patients
respectively, and a single homozygous mutation in GCK
(2.1%). In group 2, we identified one incidence of a
KCNJ11 mutation. No genetic defects were detected in
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Conclusions/interpretation Genetic mutations were identi-
fied in ~75% of non-consanguineous probands with PNDM/
MDI,usingsequentialscreeningofKCNJ11, INS and ABCC8
genes in infants diagnosed within the first 6 months of age.
This percentage decreased to 12% in those with diabetes
diagnosed between 7 and 12 months. Patients belonging to
the latter group may either carry mutations in genes different
from those commonly found in PNDM/MDI or have
developed an early-onset form of autoimmune diabetes.
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Abbreviations
CNV Copy number variation
DEND Developmental delay, epilepsy, neonatal diabetes
GADA Glutamic acid decarboxylase autoantibodies
IA-2A Tyrosine phosphatase-related proteins islet anti-
gen 2 autoantibodies
IAA Insulin autoantibodies
ICA Islet-cell antibodies
iDEND Intermediate DEND
IPEX Immune dysregulation, polyendocrinopathy,
enteropathy, X-linked
ISPED Italian Society of Pediatric Endocrinology and
Diabetology
KATP ATP-sensitive potassium channel
MDI Monogenic diabetes of infancy
MLPA Multiplex ligation-dependent probe amplification
PNDM Permanent neonatal diabetes mellitus
TNDM Transient neonatal diabetes mellitus
ZnT8A Zinc transporter 8 autoantibodies
Introduction
Permanent diabetes with onset within the first 6 months
following birth (permanent neonatal diabetes mellitus
[PNDM]/monogenic diabetes of infancy [MDI]) is a rare
condition associated with defects in genes that play major roles
in pancreatic beta cell development and function; mutations in
the genes encoding the ATP-sensitive potassium channel
(KATP) subunits, KCNJ11 (also known as KIR6.2), ABCC8
(also known as SUR1) and insulin (INS), account for most
cases of PNDM/MDI [1–6]. Mutations in both the KATP
channel and INS genes can also cause diabetes with onset in
childhood and adulthood [7–9]. In addition, KATP channel
mutations are a prominent cause of transient neonatal diabetes
mellitus (TNDM), a form of neonatal/infancy-onset diabetes
that usually remits within 6 months of its onset [1, 2, 4].
Mutations in KATP channel genes that cause PNDM/MDI are
usually activating, dominant and sporadic, but patients with
recessive mutations in ABCC8 have also been described [10].
Patients with INS gene mutations, which can be either
dominant [5, 6] or recessive [11], present with non-
syndromic diabetes. In contrast, patients carrying mutations to
KATP genes may also show variable degrees of motor/mental
developmental delay with epilepsy (developmental delay,
epilepsy, neonatal diabetes; DEND) or without epilepsy
(intermediate DEND; iDEND). Moreover, individuals with
some exceedingly rare forms of syndromic PNDM may bear
recessive mutations in several genes, including PDX1,
EIF2AK3, PTF1A, GLIS3, RFX6 or FOXP3 [12–18], while
recessivemutationsinglucokinasegiverisetoisolatedneonatal
diabetes [19]. In 2002 we reported the basis for the currently
used definition of PNDM/MDI by providing strong evidence
that permanent diabetes with onset within 6 months of life is
not autoimmune, but rather genetic, in origin [20]. This
conclusion was supported by the absence of type 1 diabetes
mellitus autoantibodies in patients presenting with diabetes in
the first 180 days of life. In the present investigation we have
assessed the power of this temporal cut-off in defining neonatal/
infancy-onset diabetes by performing sequential screening of
KCNJ11, INS and ABCC8 genes in 54 patients with permanent
diabetes: 46 patients with onset of the disease within 6 months
from birth, and eight patients between 7 months and 1 year of
age. In those who were negative for mutations in the initial
screening, five other candidate genes (ERN1, CHGA, CHGB,
NKX6-1 and CACNA1C) were sequenced. In specific patients,
GCK, FOXP3, NEUROG3 and CDK4 genes and gene copy
number variations were also evaluated.
Methods
Probands A total of 46 patients with diabetes onset before
6 months of age (17, or 37%, with onset within the first
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1694 Diabetologia (2011) 54:1693–17016 weeks of life) (group 1) and eight patients with diabetes
diagnosed between 7 and 12 months (group 2) were
included in this study. Of these 54 patients, 22 patients in
group 1 and two in group 2 have not been reported
previously. Most probands studied in the present investiga-
tion were of Italian descent, except for one of Moroccan
(nd-VI/1), one of Albanian (nd-MI/3), one of Chinese (nd-
MO/3) and one of Masai descent (nd-RM/6; Table 1). Family
history disclosed consanguinity only in the Albanian family.
In group 1, a male patient (deceased; nd-BR/1) presented
with a phenotype resembling IPEX (immune dysregula-
tion, polyendocrinopathy, enteropathy, X-linked) syn-
drome [18]. Two other infants had syndromic diabetes
with a phenotype that was different from DEND/iDEND,
o ra n yo t h e rf o r mc a u s e db yk n o w ng e n e s[ 12–17]. One of
these (group 1) suffered from episodes of liver insuffi-
ciency, with high ammonium and transaminase levels and
low albumin, but with a mute liver biopsy; he also
presented with anaemia that was successfully treated with
erythropoietin (nd-NA/2). The other patient (group 2)
Table 1 Clinical and genetic features of patients with diabetes onset within the first year of life studied in the present investigation
Patient T1D autoantibodies tested Age at onset
(days)
Gene variant Other features SU treatment
Group 1
nd-VI/1 ICA, GADA, IA-2A 1 KCNJ11/V59A DEND Yes
nd-BR/1 None 2 – Diarrhoea
nd-RM/4 IAA, GADA, IA-2A 2 KCNJ11/R201S Yes
nd-MI/3 IAA, GADA, IA-2A, ZnT8A 2 KCNJ11/R201C Yes
nd-PD/2 None 3 ABCC8/L213P DEND Yes
nd-FI/1 None 15 ABCC8/V324M;
ABCC8/W688R
Yes
nd-CT/2 None 27 –
nd-MI/2 ICA, GADA, IA-2A 38 KCNJ11/K170R Yes
nd-LE/2 ICA, IAA, GADA, IA-2A 39 –
nd-PR/2 None 40 ABCC8/L213P iDEND Yes
nd-NA/1 None 40 KCNJ11/R201C Yes + insulin
nd-CT/1 none 60 KCNJ11/V59M iDEND Yes
nd-NA/2 ICA, GADA, IA-2A 71 ABCC8/A355T Anaemia Yes + insulin
nd-MO/3 ICA, IAA, GADA 73 KCNJ11/H46Y Yes
nd-RM/4 IAA, GADA, IA-2A 80 –
nd-TO/3 GADA, IA-2A 82 –
nd-TS/2 None 120 KCNJ11/V59M iDEND Yes
nd-RM/6 None 120 KCNJ11/R195H
a
nd-RM/5 IAA, GADA, IA-2A 135 KCNJ11/E322K Yes
nd-PI/1 ICA 141 –
nd-BG/1 GADA 180 ABCC8/S1054N
a
nd-CES/3 None 190 –
Group 2
mdi-RM/3 None 220 KCNJ11/V59M iDEND Yes
mdi/NA-B/1 ICA 251 –
mdi-PA/1 ICA, IAA, GADA, IA-2A 270 –
mdi-RM-OBG/1 IAA, GADA 289 – Muscle hypotrophy
mdi-CES/1 ICA, IAA 300 –
mdi-RM-OBG/3 IAA, GADA, IA-2A 330 –
mdi-RM-OBG/2 IAA, GADA, IA-2A 330 –
mdi-NA/2 GADA, IA-2A 354 –
SU treatment denotes complete withdrawal of insulin therapy unless specified. Mutations KCNJ11/H46Y and KCNJ11/V59A were found in
probands with Chinese and Moroccan ancestry, respectively. The Albanian patient carried mutation KCNJ11/R201C
T1D type 1 diabetes, SU sulfonylurea
aBenign gene variants
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puberty and retarded growth (mdi-RM-OBG/1).
Type 1 diabetes autoantibodies Twenty-seven patients in
group 1 and all patients in group 2 tested negative for at
least one type 1 diabetes autoantibody (i.e. ICA [islet cell
autoantibodies], IAA [insulin autoantibodies], GADA [glu-
tamic acid decarboxylase autoantibodies], IA-2A [tyrosine
phosphatase-related proteins islet antigen 2 autoantibodies]
or ZnT8A [zinc transporter 8 autoantibodies]) evaluated at
the time of diagnosis.
Genetic testing Informed consent was obtained at each
local paediatric diabetes centre involved in the study.
Genomic DNA was extracted from peripheral lympho-
cytes by DNeasy Tissue Isolation kit (Qiagen, Valencia,
C A ,U S A ) ,a m p l i f i e db yP C Ra n ds e q u e n c e du s i n ga
DNA automated sequencer (Applied Biosystems ABI
3730, Foster City, CA, USA). Based on their frequency,
our current routine for new cases is to sequence
KCNJ11 and INS genes at the same time and, if no
mutation is found, the larger ABCC8 gene is examined
[4, 6, 21]. In those patients where no mutation was
identified, the entire coding region of the following
candidate genes, ERN1, CHGA, CHGB, NKX6-1 (in patients
in groups 1 and 2) and CACNA1C ( i ng r o u p1o n l y ) ,w e r e
sequenced. CACNA1C [22], which encodes voltage-
dependent L-type calcium channel subunit alpha-1C
(CAV1.2), CHGA, CHGB [23]a n dERN1 [24]w e r ec h o s e n
for their role in insulin secretion; NKX6-1 was selected
because of its role in endocrine pancreas development [25].
In particular, ERN1 encodes inositol-requiring protein 1
(IRE1A), which is involved in the unfolded protein response
and insulin biosynthesis [24]. FOXP3 and NEUROG3 were
sequenced in the proband with IPEX-like features [18, 26],
CDK4 in the proband with diabetes and muscle hypotrophy
[27], and GCK in patients presenting with diabetes onset in
the first week of life, together with low birthweight [19].
Primer sequences and PCR conditions for candidate genes
are listed in Table 1 of the electronic supplementary material
(ESM).
New variants in KATP genes were searched by DNA direct
sequencing of genomic DNA from 50 normal controls.
The multiplex ligation-dependent probe amplification
(MLPA) technique (MRC-Holland, Amsterdam, the
Netherlands) was ap p l i e dt os e a r c hf o rABCC8 gene
deletions. In two patients with syndromic diabetes, copy
number variations (CNVs) were also assessed. Patients’
genomic DNA was analysed with the GeneChip 6.0
microarray (Affymetrix, Santa Clara, CA, USA). Labelled
DNA was hybridised for 16–18 h; the chip was washed,
stained and scanned using a Scanner 3000 7G (Affymetrix).
The generated file, containing a single intensity value
calculated for each probe, was loaded into Genotyping
Console 3.0.2 and the SNP 6.0 copy number calls from
270 International HapMap Project control samples (www.
hapmap.org/) were used as a reference model file for
comparison. CNVs were selected based on variables
previously described [28].
PNDM/MDI incidence in Italy Information was obtained
from the Italian network database on early-onset diabetes
(presentation within the first 24 months of life). The
database works under the auspices of the Italian Society of
Pediatric Endocrinology and Diabetology (ISPED) and
collects clinical data from 45 paediatric diabetes clinics,
which are the referral centres for the diagnosis and treatment
of patients with neonatal and childhood diabetes in Italy.
Incidence rates per 100,000 live births were computed
for cases that developed diabetes in the first 6 months of
life and were born between 1995 and 2009. For compar-
ison, we also calculated incidence rates utilising the old
(1995) limit of ≤42 days of life for the diagnosis of PNDM
[29]. Confidence intervals for incidence rates were estimat-
ed using the exact Poisson distribution.
Results
Disease-causing mutations in KATP genes In group 1,
heterozygous mutations in the KCNJ11 gene were identi-
fied in 23 patients (50%), including 14 probands previously
reported by our group [21, 30–32]. All mutations were
considered to be de novo, because parental DNA sequenc-
ing disclosed wild-type KCNJ11 genes. Table 1 shows
mutations recently or previously identified in patients with
PNDM/MDI, including H46Y (nd-MO/3) [33], V59A (nd-
VI/1) [34], V59M, K170R, R201C and E322K (nd-RM/25;
Table 1)[ 35]. We also identified a new substitution,
arginine by serine, in codon 201 (R201S, c.601C>A), that
we believe is novel (nd-RM/4). In Group 2, we found the
previously described KCNJ11/V59M mutation [3, 21]i na
patient with diabetes diagnosed at 220 days of life (mdi-
RM/3). ABCC8 gene sequencing led to the identification of
five heterozygous mutations in four probands from group 1.
ABCC8/L213P (c.638T>C) was found to be a de novo
mutation in a patient with complete DEND syndrome (nd-
PD/2), and in a second proband with iDEND, who had
inherited the mutation from her father (Fig. 1), who also
presented with iDEND (nd-PR/2). A mutation in the same
codon, ABCC8/L213R, has been previously reported in
association with iDEND [36]. Of our patients, one proband
was a compound heterozygote for the ABCC8/V324M
mutation, previously described in patients with the transient
form of the disease (TNDM) [36], who usually need insulin
therapy for less than 1 year [4], and for the novel W688R
1696 Diabetologia (2011) 54:1693–1701(c.2062T>G) mutation (nd-FI/1). Residue W688 is con-
served in dog, cow, mouse, chicken and zebra fish. Because
both of the patient’s parents were deceased, we analysed the
grandparents’ DNA and confirmed the ABCC8/V324M
mutation in the maternal grandfather and the ABCC8/
W688R mutation in the paternal grandmother (Fig. 1).
After identifying the mutations, an OGTT was done in both
patients; the carrier for V324M was diagnosed with
diabetes (2 h plasma glucose 14 mmol/l) and the carrier
for W688R presented with impaired glucose tolerance (2 h
plasma glucose 8.4 mmol/l). Finally, a patient carrying the
unreported ABCC8/A355T (c.1063G>A; nd-NA/2) variant
inherited the mutation from his mother, who was diagnosed
with gestational diabetes at the age of 26 years. Residue
A355 is conserved in dog, cow, rat, mouse and chicken, but
not in zebra fish, where it is substituted by glycine. None of
the new KCNJ11 or ABCC8 mutations was detected in 100
chromosomes from normal controls.
Polymorphisms—KATP genes In the patient of Masai
descent (nd-RM/6) we detected the variant KCNJ11/
R195H (c.584G>A; single nucleotide polymorphism:
rs5217; Table 1), while in the proband nd-BG/1 we found
the variant ABCC8/S1054>N (c.3161G>A, numbered
according to [36]; Table 1), inherited from the patient’s
father, who had normal glucose tolerance. MLPA of the
ABCC8 gene did not disclose any deletion in this patient.
Thus, we currently classify ABCC8/S1054N as a rare,
benign variant, taking into account the fact that residue
S1054 is conserved from dog through to mouse, but not in
chicken and zebra fish, where is substituted by cysteine and
valine, respectively.
No additional mutations were found in INS (6), GCK
(19) or any of the other genes (FOXP3, NEUROG3, ERN1,
CHGA, CHGB, NKX6-1, CACNA1C and CDK4) screened
at this time.
Clinical features in patients with diabetes and negative
for KCNJ11, INS and ABCC8 Patients from group 1,
negative in the genetic screening for genes commonly
causing PNDM/MDI (hereafter called PNDM/MDI ‘X’)
had a higher birthweight (median 3,164 g) than patients
with KCNJ11 mutations (median 2,460 g; p<0.0003), and
similar to individuals carrying INS mutations (Table 2).
Moreover, in patients with PNDM/MDI ‘X’, diabetes was
diagnosed 1 month later (median) than carriers of mutations
of KATP genes.
Incidence of PNDM/MDI in Italy The incidence of
PNDM/MDI was calculated at 1:210,287 (95% CI
1:300,300–1:151,976) live births for years 1995–2009.
Of note, 22 out of 23 patients (95%) included in the
database for years 2000–2009 (incidence rate:
1:213,198, 95% CI 1:336,700–1:142,045) have been
subjected to genetic screening for KCNJ11, INS and
ABCC8 and 15 (68%) carried a causative mutation in
either KCNJ11 or INS. The incidence rate (years 1995–
2009) was found to be 1:473,146 when calculated using
the original definition of neonatal diabetes as insulin-
requiring hyperglycaemia with onset within the first
6 weeks of life [29].
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Fig. 1 Pedigrees of four families with mutations in ABCC8; from top
to bottom: mutation, phenotype, age at presentation/diagnosis of
diabetes, current age and initial therapy for diabetes. For the two
grandparents of proband nd-FI/1, OGTT tests were performed at 70
(W688R) and 74 (V324M) years of age. GD, gestational diabetes;
IGT, impaired glucose tolerance; INS, insulin
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In 2002wesuggestedthat thecause ofdiabetes inpatientswith
disease onset within 6 months of life might be genetic [20]. At
that time only one gene, GCK [19], was known to be linked
with rare cases of insulin-deficient diabetes, while IPF1 (also
known as PDX1), EIF2AK3 and FOXP3 had been associated
with early onset, syndromic diabetes [12, 13, 18]. More
recently, mutations in the KCNJ11, ABCC8 and INS genes
have been identified, which cause diabetes with onset in the
first 6 months of life [3–6] and beyond [7–9, 37]. In the
present study, we report the identification, by sequential
sequencing of the three latter genes, of a disease-causing
mutation in 36 probands with diabetes diagnosed before
6 months of age and in a single patient with diabetes onset
after 6 months but before 1 year of age. In Group 1, novel
mutations in KCNJ11/R201S, ABCC8/L213P and ABCC8/
W688R were identified. The latter was found in a patient who
also carried the TNDM-causing ABCC8/V324M mutation
[36]. PNDM/MDI can result from recessive ABCC8 muta-
tions, usually one with a mild activating effect and the other
with loss-of-function, which are observed in recessive
hyperinsulinism [10]. In our case, however, we favour the
hypothesis that both ABCC8/V324M and ABCC8/W688R are
mildly activating, based on the fact that W688R is associated
with impaired glucose tolerance in the paternal grandmother.
In contrast, we cannot explain at this time the extremely
different phenotypes we observed in the carriers of the
mutation ABCC8/A355T, who show either PNDM/MDI or
gestational diabetes. Previously, phenotypic variability in
ABCC8 mutation carriers has been described in families in
which the proband presents with TNDM and first-degree
relatives carry the same mutation showing early-onset type 2
diabetes or even normal glucose tolerance [7, 38]. Because
the patient with ABCC8/A355T also has a liver-related and
haematologic phenotype, it is conceivable that he may carry a
mutation in another locus that impacts on glucose metabo-
lism. Functional studies are definitely needed to firmly
establish the impact of ABCC8/A355T on insulin secretion.
Inthepresentwork,themutationdetectionrateofKCNJ11,
INS and ABCC8 genes was 78.2% (36/46) for patients in
group 1 and 12.5% (1/8) for patients in group 2. After
sequencing the same three genes, Støy et al. [39]o b t a i n e d
comparable results, with a 63% and 6.6% detection rate in
patients for permanent diabetes before or after 6 months of
life, respectively. Our results from group 1 were not
influenced by type 1 diabetes autoantibody status, which
was unknown in 15 (40%) patients who harboured a disease-
causing mutation [6, 21, 30–32]( T a b l e1).
Sequencing of KCNJ11, INS and ABCC8 in patients
from group 2 was justified by the fact that mutations in
these genes have previously been detected in patients with
diabetes onset in infancy, childhood and even adulthood
[7–9, 37, 38 and F. Barbetti, unpublished observations],
eliciting a negative result in >85% of cases examined.
Screening of candidate genes in these and other patients
was also negative [present study; 40]. Consequently, the
autoimmune or genetic aetiology for seven of the remaining
patients in group 2 remains open. Four patients tested
negative for IAA, which are found at an increased rate in
individuals with diabetes onset before 5 years of age, and
one of these four was negative for all autoantibodies
commonly used as tools for the diagnosis of type 1
diabetes. However, the latter patient may still harbour
autoantibodies against ZnT8A, which can be detected as a
single autoantibody in patients with type 1 diabetes
previously classified as autoantibody-negative on the basis
of existing markers (i.e. IAA, GADA, IA-2A and ICA)
[9, 41]. Of note, one patient who was negative to GADA at
diagnosis (and carrying HLA-DR3/DR4) and was initially
included in group 2 became weakly GADA positive during
the study; this individual was therefore re-classified as
having type 1 diabetes and was not investigated further. A
limitation/weakness of our study is that the HLA status of
most patients in group 2 was unknown, and type 1 diabetes
autoantibodies were not thoroughly tested.
Conversely, we think that the nine patients in group 1
who had no disease-causing mutation identified, and
possibly the patient carrying the ABCC8/A355T mutation,
who showed clinical features not associated with mutations
to KATP channel genes, are likely to carry a mutation in a
locus that has not, as yet, been found. Seven of these
Table 2 Birthweight and age at diabetes onset of probands with KCNJ11, INS and ABCC8 mutations and of unknown genetic origin
Gene KCNJ11 INS ABCC8 Unknown
n 22 9 4 8
Birthweight (g) 2,460±394.34 3,050±203.88
† 2,825±663.79 3,150±204.57
‡
Age at diagnosis (days) 53±59.7 86±45.6 275±30.0 82±68.9
Birthweight and age at diabetes onset are median values±SD
BirthweightwasnotavailableforonepatientcarryingaKCNJ11 mutation, and for a second patient born in Kenya (nd-RM/6). The patient with IPEX-
like features (birthweight 990 g, born at 22 weeks of gestation) was not included in the group of unknown genetic aetiology (PNDM/MDI ‘X’)
p value vs KCNJ11:
†0.009,
‡0.003
1698 Diabetologia (2011) 54:1693–1701patients presented with non-syndromic diabetes and birth-
weight close to normal (Table 2) and were not good
candidates for screening of any of the known genes giving
rise to syndromic diabetes [12–17] or hyperglycaemia in
the first week of life [42, 43]. We therefore sequenced
genes that we considered to be candidates, based on the
phenotypic consequences of their manipulation/ablation in
mice [22–25], with no success. Because hundreds of genes
can have an impact on pancreatic beta cell function [44]w e
believe that new approaches, such as whole exome/genome
sequencing, should be used in the future for PNDM/MDI
gene discovery [45, 46].
The incidence rate of PNDM/MDI in Italy, utilising the
6 month limit as a cut-off for diagnosis of neonatal/infancy-
onset diabetes, is about 1:210,000 live births. This result is
comparable to recent reports from Slovakia, the UK, the
Netherlands and Poland [47, 48], showing an incidence of
PNDM/MDI of 1:215,417 [47] and 1:260,000 [48],
respectively. In summary, a molecular genetic diagnosis
can be reached in ~75% of patients with diabetes onset
≤6 months of age when KCNJ11, INS and ABCC8 genes
are sequenced in populations with a low consanguinity rate.
Moreover, because the status of type 1 diabetes autoimmu-
nity was unknown in about 40% of patients in this group,
we also conclude that knowledge of type 1 diabetes
autoantibodies is not a prerequisite to proceeding to genetic
screening, which we recommend for all patients with
diabetes onset before 6 months of age. The incidence of
PNDM/MDI varies, as expected, if different age cut-offs for
disease onset are used as criteria for aetiological (genetic vs
autoimmune) diagnosis.
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